Del Rosso J Q, Zellis S, Gupta A K
University of Nevada School of Medicine, Las Vegas, USA.
J Am Osteopath Assoc. 1998 Sep;98(9):497-502.
Superficial cutaneous and mucosal Candida infections are common and widely affect both the immunocompromised as well as the immunocompetent populations. Common infections may include Candida paronychia, cutaneous candidiasis, oral candidiasis, vulvovaginal candidiasis, and Candida onychomycosis. Although C albicans has been considered to be the most common pathogen, other Candida species have emerged as potential causes of certain infections. Currently, a variety of antifungal agents is available to treat these infections. They include fluconazole, ketoconazole, and itraconazole. These agents have been widely used to treat fungal infections, including superficial and systemic candidiasis. However, some concerns exist regarding safety associated with long-term use of ketoconazole, and emerging issues of Candida resistance to fluconazole in some patient subsets have been reported. Itraconazole has proven efficacy in treating cutaneous and mucosal Candida infections. Additionally, studies have demonstrated that itraconazole may have increased efficacy and an excellent safety profile when administered in a pulse-dose, or intermittent fashion, for superficial mycotic infections. Itraconazole is an effective agent that warrants consideration when selecting treatment for Candida infections.
浅表皮肤和黏膜念珠菌感染很常见，广泛影响免疫功能低下和免疫功能正常人群。常见感染可能包括念珠菌性甲沟炎、皮肤念珠菌病、口腔念珠菌病、外阴阴道念珠菌病和念珠菌性甲癣。虽然白色念珠菌一直被认为是最常见的病原体，但其他念珠菌属已成为某些感染的潜在病因。目前，有多种抗真菌药物可用于治疗这些感染。它们包括氟康唑、酮康唑和伊曲康唑。这些药物已被广泛用于治疗真菌感染，包括浅表和全身性念珠菌病。然而，长期使用酮康唑的安全性存在一些担忧，并且已报道在一些患者亚组中出现念珠菌对氟康唑耐药的新问题。伊曲康唑已被证明对治疗皮肤和黏膜念珠菌感染有效。此外，研究表明，伊曲康唑以脉冲剂量或间歇方式给药治疗浅表真菌病时，可能具有更高的疗效和出色的安全性。伊曲康唑是一种有效的药物，在选择念珠菌感染的治疗方法时值得考虑。
